Enovix Corporation's stock experienced a significant pre-market plunge of 5.69% following the release of disappointing financial results and forward guidance.
The sell-off was driven by the company's weak Q1 2026 revenue forecast of $6.5 million to $7.5 million, which fell short of analyst estimates. Additionally, the company reported a 17.8% year-over-year decline in Q4 revenue to $7.99 million, missing expectations, and a substantial 218% surge in interest expenses for the full year 2025.
Further pressure came from analyst actions, including Canaccord Genuity cutting its price target on Enovix from $21 to $15, reflecting growing concerns about the company's near-term growth prospects and financial performance.
Comments